June 2019 - Volume 3 - Issue - Contributor Index

Author:
N, L. K
Author:
Nabhan, C.

FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY: PF381

Rhodes, J.; Sail, K.; Yazdy, Sarraf M.; More

HemaSphere. 3:142, June 2019.

Author:
Nabil, N.
Author:
Nadal, N.

B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS: PB1868

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3:851-852, June 2019.

INCOMPLETE COUNT RECOVERY IN PATIENTS WITH COMPLETE REMISSION PRIOR TO ALLOGENEIC HCT FOR AML IS ASSOCIATED WITH A HIGH NON-RELAPSE MORTALITY WITHOUT AN INCREASED RELAPSE RISK: S1626

Innes, A.; Wooley, P.; Szydlo, R.; More

HemaSphere. 3:751-752, June 2019.

Author:
Nadali, G.

ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY: PS1267

Cattaneo, C.; Gramegna, D.; Busca, A.; More

HemaSphere. 3:580-581, June 2019.

Author:
Nadarajah, N.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

Author:
Nadeu, F.

THE PROLIFERATIVE HISTORY SHAPES THE DNA METHYLOME OF B-CELL TUMORS AND PREDICTS CLINICAL OUTCOME: S843

Duran-Ferrer, M.; Clot, G.; Nadeu, F.; More

HemaSphere. 3:376, June 2019.

Author:
Nadine, R.

HACE1, A NOVEL TUMOR SUPPRESSOR GENE WHICH REGULATE THE RESPONSE OF VENETOCLAX, GANT61 AND NECROPTOSIS ACTIVATORS BY CONTROLLING C-FLIP, GLI2 AND BCL2 GENES IN ACUTE MYELOID LEUKEMIA: PS1001

Garitano, A.; Teufel, E.; Kreckel, J.; More

HemaSphere. 3:450, June 2019.

Author:
Nador, G.

EFFICACY OF BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH CARFILZOMIB-REFRACTORY MYELOMA IN THE UK NCRI CARDAMON TRIAL: PF599

Phillips, E.; Wilson, W.; Benjamin, R.; More

HemaSphere. 3:252-253, June 2019.

Author:
Nag, A.
Author:
Nagae, G.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

Author:
Nagai, H.

REDUCED-INTENSITY IMMUNOCHEMOTHERAPY WITHOUT VINCRISTINE IN ELDERLY PATIENTS OLDER THAN 80 YEARS OLD WITH DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL: PF301

Yoshida, I.; Suehiro, Y.; Hirabayashi, Y.; More

HemaSphere. 3:102-103, June 2019.

LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA: PS1259

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3:575-576, June 2019.

Author:
Nagao, S.

SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION: PS1435

Kato, S.; Maekawa, T.; Ogata, K.; More

HemaSphere. 3:661-662, June 2019.

Author:
Nagashima, T.

EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY: PF184

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3:44, June 2019.

Author:
Nagata, H.
Author:
Nagata, Y.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

Author:
Nagate, Y.
Author:
Naggy, N.
Author:
Nagler, A.

POST-TRANSPLANT CYCLOPHOSPHAMIDE VS ATG FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN T-REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT OF THE ALWP/EBMT: S114

Nagler, A.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3:9, June 2019.

IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD: S115

Baron, F.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3:9-10, June 2019.

OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS: PF602

Montefusco, V.; Gay, F.; Spada, S.; More

HemaSphere. 3:254-255, June 2019.

Author:
Nagler, M.
Author:
Nagtegaal, T.
Author:
Nagy, B. Jr.
Author:
Nagy, E.
Author:
Nagy, G.
Author:
Nagy, N.

EZH2 GAIN-OF-FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A PRELIMINARY ANALYSIS ON 590 PATIENTS: PS1247

Bödör, C.; Batlevi, C.; Nagy, N.; More

HemaSphere. 3:568-569, June 2019.

Author:
Nagy, Z.

UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS: PF296

Duell, J.; Maddocks, K.; Barca, González E.; More

HemaSphere. 3:100, June 2019.

LONG TERM FOLLOW-UP OF PNH PATIENTS TREATED WITH THE SMART ANTI-HC5 ANTIBODY (SKY59/RO7112689) IN THE OPEN LABEL EXTENSION (OLE) OF THE COMPOSER TRIAL: PF348

Röth, A.; Nagy, Z.; de Latour, Peffault R.; More

HemaSphere. 3:125-126, June 2019.

Author:
Nahi, H.

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA: PF592

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3:248-249, June 2019.

FASTER & SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D-RD) VS RD: MAIA: PF603

Perrot, A.; Facon, T.; Plesner, T.; More

HemaSphere. 3:255, June 2019.

RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA: S823

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3:364, June 2019.

Author:
Nahi, H. N.

CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION: S1602: FOLLOWING SALVAGE ASCT IN MULTIPLE MYELOMA: A RANDOMIZED PHASE 2 TRIAL BY THE NORDIC MYELOMA STUDY GROUP

Gregersen, H.; Peceliunas, V.; Remes, K.; More

HemaSphere. 3:737-738, June 2019.

Author:
Nai, A.
Author:
Nair, S.
Author:
Nair, V.
Author:
Najim, Z.
Author:
Najjar, L.
Author:
Najjar, O.
Author:
Nakagawa, M.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA: PS983

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3:442, June 2019.

COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN: PS1367

Kanamori, T.; Sanada, M.; Ri, M.; More

HemaSphere. 3:624-625, June 2019.

Author:
Nakagawa, M. M.
Author:
Nakahara, E.
Author:
Nakai, R.
Author:
Nakajima, K.
Author:
Nakamae, H.

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4: PF407

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3:155-156, June 2019.

Author:
Nakamae, M.
Author:
Nakamaki, T.

NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS: S135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

Author:
Nakamaru, K.
Author:
Nakamura, A.
Author:
Nakamura, S.

LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA: PS1259

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3:575-576, June 2019.

CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012): PS1263

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3:578, June 2019.

Author:
Nakane, T.
Author:
Nakanishi, T.
Author:
Nakanishi, Y.
Author:
Nakano, H.

COMPARISON OF ALEMTUZUMAB, ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE GRAFT-VS-HOST DISEASE AND GRAFT-VS-LEUKEMIA EFFECT IN XENOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: PF784

Mashima, K.; Oh, I.; Fujiwara, K.; More

HemaSphere. 3:345-346, June 2019.

Author:
Nakano, R.
Author:
Nakao, S.

THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY: PS1115

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3:504-505, June 2019.

Show: